[Form 4/A] Processa Pharmaceuticals, Inc. Amended Insider Trading Activity
Geraldine Pannu, a director of Processa Pharmaceuticals, Inc. (PCSA), filed an amended Form 4 to correct prior reporting of her restricted stock and resulting direct beneficial ownership. The amendment discloses an acquisition code A for 31,206 shares of restricted stock acquired with a $0 price and underlying 31,206 shares of common stock. After the correction, Ms. Pannu directly beneficially owns 36,275 shares of common stock. The restricted shares are subject to vesting and will vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. The filing states the amendment retracts a prior Form 4 that was filed in error and corrects the beneficially owned shares previously reported.
Geraldine Pannu, direttrice di Processa Pharmaceuticals, Inc. (PCSA), ha presentato un modulo Form 4 modificato per correggere la segnalazione precedente delle sue azioni ristrette e della relativa proprietà diretta beneficiaria. La modifica rivela un codice di acquisizione A per 31.206 azioni di azioni ristrette acquisite a prezzo di 0 $ e le 31.206 azioni comuni sottostanti. Dopo la correzione, la signora Pannu possiede direttamente 36.275 azioni ordinarie. Le azioni ristrette sono soggette a vesting e vestiranno nella prima delle date: 28 giugno 2025 o la prossima assemblea annuale degli azionisti, soggette a determinati requisiti di distribuzione. La compilazione indica che la modifica ritira un precedente Form 4 presentato per errore e corregge le azioni possedute riportate in precedenza.
Geraldine Pannu, directora de Processa Pharmaceuticals, Inc. (PCSA), presentó un Formulario 4 enmendado para corregir la información previa sobre su propiedad directa de acciones restringidas. La enmienda revela un código de adquisición A para 31,206 acciones de acciones restringidas adquiridas a un precio de $0 y las 31,206 acciones comunes subyacentes. Tras la corrección, la Sra. Pannu posee directamente 36,275 acciones comunes. Las acciones restringidas están sujetas a vesting y se adquirirán en la más temprana entre 28 de junio de 2025 o la próxima asamblea anual de accionistas, sujeto a ciertos requisitos de distribución. La presentación indica que la enmienda retracta un Formulario 4 anterior presentado por error y corrige las acciones propiedad reportadas previamente.
제럴딘 파누는 Processa Pharmaceuticals, Inc. (PCSA)의 이사로서, 제한 주식의 이전 보고를 수정하기 위해 수정된 Form 4를 제출했습니다. 수정안은 A 코드로 31,206주에 해당하는 제한 주식은 가격이 $0이며 기초 주식으로 31,206주가 포함되어 있음을 보고합니다. 수정 후 파누 여사는 직접적으로 36,275주의 보통주를 실질 보유합니다. 제한 주식은 vesting 대상이며 가장 이른 시점인 2025년 6월 28일 또는 주주총회일에 vesting되며, 특정 배당 요건의 적용을 받습니다. 이번 제출은 수정으로 이전에 잘못 제출된 Form 4를 철회하고 이전에 보고된 보유 주식을 수정한다고 명시합니다.
Geraldine Pannu, directrice chez Processa Pharmaceuticals, Inc. (PCSA), a déposé un Form 4 amendé afin de corriger le reporting antérieur de ses actions restreintes et de la propriété directe bénéficiaire qui en résulte. L’amendement indique un code d’acquisition A pour 31 206 actions restreintes acquises à un prix de 0 $ et les 31 206 actions ordinaires sous-jacentes. Après correction, Mme Pannu détient directement 36 275 actions ordinaires. Les actions restreintes sont soumises à vesting et vestiront à la première des dates: 28 juin 2025 ou la prochaine assemblée annuelle des actionnaires, sous réserve de certaines conditions de distribution. Le dépôt indique que l’amendement retire un Form 4 antérieur déposé par erreur et corrige les actions détenues indiquées précédemment.
Geraldine Pannu, Direktorin bei Processa Pharmaceuticals, Inc. (PCSA), hat ein geändertes Form 4 eingereicht, um die frühere Meldung ihrer eingeschränkten Aktien und der daraus resultierenden direkten wirtschaftlichen Eigentümerschaft zu korrigieren. Die Änderung offenbart einen Erwerbs-Code A für 31.206 Stücke eingeschränkter Aktien, die zu einem Preis von 0 $ erworben wurden, sowie darunter liegende 31.206 Stücke Stammaktien. Nach der Korrektur besitzt Frau Pannu direkt 36.275 Stammaktien. Die eingeschränkten Aktien unterliegen einer Vesting-Phase und werden am frühesten der 28. Juni 2025 oder der nächsten Jahreshauptversammlung der Aktionäre vesten, vorbehaltlich bestimmter Ausschüttungsanforderungen. Die Einreichung erklärt, dass das Amendment ein zuvor fehlerhaft eingereichtes Form 4 zurückzieht und die zuvor gemeldeten wirtschaftlich berechtigten Aktien korrigiert.
جيرالدين بانّو، مديرة في شركة Processa Pharmaceuticals, Inc. (PCSA)، قدمت نموذج Form 4 معدّل لتصحيح الإبلاغ السابق عن أسهمها المقيدة وملكيتها الفعليّة الموزَّعة. يكشف التعديل عن رمز الاستحواذ A لـ31,206 سهمًا من الأسهم المقيدة اشتُريَت بسعر $0 والأسهم العادية الأساسية 31,206. بعد التصحيح، تملك السيدة بانّو مباشرة 36,275 سهمًا من الأسهم العادية. الأسهم المقيدة خاضعة لـ vesting وستكتسب الملكية في أقرب موعد وهو 28 يونيو 2025 أو الاجتماع السنوي القادم للمساهمين، رهناً بمتطلبات توزيع محددة. تشير العريضة إلى أن التعديل يسحب Form 4 سابقاً مبلّغ عنه بالخطأ ويصحّح الأسهم المملوكة الموثقة سابقاً.
杰拉尔丁·潘努，Processa Pharmaceuticals, Inc.（PCSA）的董事，提交了修订的 Form 4，以纠正其受限制股票的先前报告及直接实益拥有权。该修正披露了用于以零价购买的 A 代码的 31,206 股受限制股票，以及相应的 31,206 股普通股的下层股票。更正后，潘努女士直接实际拥有 36,275 股普通股。受限制股票受 vesting 约束，并将在最早的日期生效，即 2025年6月28日 或股东年会之前，须符合特定分配要求。 filing 表示该修订撤回了先前因错误提交的 Form 4，并更正了先前报告的受益股数。
- Correction filed to amend and retract a prior erroneous Form 4, improving public disclosure accuracy
- Clear vesting terms disclosed: restricted shares vest on the earlier of June 28, 2025 or the next annual meeting, providing transparency on timing
- Prior Form 4 filed in error, indicating a previous reporting mistake that required correction
Insights
TL;DR: Amendment clarifies insider ownership of 36,275 shares after correcting an earlier erroneous Form 4.
The amended Form 4 provides clarity on the director's holdings, showing a $0 acquisition of 31,206 restricted shares that underlie the same number of common shares and result in total direct beneficial ownership of 36,275 shares. This is a routine equity compensation disclosure rather than a market-moving transaction. The correction improves the accuracy of public records, which is important for investor transparency and compliance with Section 16 reporting requirements. No sale or cash purchase is reported and no new dilution or change to outstanding shares is indicated in this filing.
TL;DR: The filing is a corrective disclosure addressing a prior reporting error and details time-based vesting conditions.
The amendment documents that the restricted stock grant vests on a specified corporate event (earlier of a calendar date or the next annual meeting) and confirms the director's direct ownership figure. Correcting a prior erroneous filing demonstrates attention to compliance processes, though the presence of an error initially suggests controls around Section 16 filings could be reviewed. The nature of the award appears to be regular compensation-related restricted stock rather than performance-based equity, as vesting is event- and date-based per the explanation provided.
Geraldine Pannu, direttrice di Processa Pharmaceuticals, Inc. (PCSA), ha presentato un modulo Form 4 modificato per correggere la segnalazione precedente delle sue azioni ristrette e della relativa proprietà diretta beneficiaria. La modifica rivela un codice di acquisizione A per 31.206 azioni di azioni ristrette acquisite a prezzo di 0 $ e le 31.206 azioni comuni sottostanti. Dopo la correzione, la signora Pannu possiede direttamente 36.275 azioni ordinarie. Le azioni ristrette sono soggette a vesting e vestiranno nella prima delle date: 28 giugno 2025 o la prossima assemblea annuale degli azionisti, soggette a determinati requisiti di distribuzione. La compilazione indica che la modifica ritira un precedente Form 4 presentato per errore e corregge le azioni possedute riportate in precedenza.
Geraldine Pannu, directora de Processa Pharmaceuticals, Inc. (PCSA), presentó un Formulario 4 enmendado para corregir la información previa sobre su propiedad directa de acciones restringidas. La enmienda revela un código de adquisición A para 31,206 acciones de acciones restringidas adquiridas a un precio de $0 y las 31,206 acciones comunes subyacentes. Tras la corrección, la Sra. Pannu posee directamente 36,275 acciones comunes. Las acciones restringidas están sujetas a vesting y se adquirirán en la más temprana entre 28 de junio de 2025 o la próxima asamblea anual de accionistas, sujeto a ciertos requisitos de distribución. La presentación indica que la enmienda retracta un Formulario 4 anterior presentado por error y corrige las acciones propiedad reportadas previamente.
제럴딘 파누는 Processa Pharmaceuticals, Inc. (PCSA)의 이사로서, 제한 주식의 이전 보고를 수정하기 위해 수정된 Form 4를 제출했습니다. 수정안은 A 코드로 31,206주에 해당하는 제한 주식은 가격이 $0이며 기초 주식으로 31,206주가 포함되어 있음을 보고합니다. 수정 후 파누 여사는 직접적으로 36,275주의 보통주를 실질 보유합니다. 제한 주식은 vesting 대상이며 가장 이른 시점인 2025년 6월 28일 또는 주주총회일에 vesting되며, 특정 배당 요건의 적용을 받습니다. 이번 제출은 수정으로 이전에 잘못 제출된 Form 4를 철회하고 이전에 보고된 보유 주식을 수정한다고 명시합니다.
Geraldine Pannu, directrice chez Processa Pharmaceuticals, Inc. (PCSA), a déposé un Form 4 amendé afin de corriger le reporting antérieur de ses actions restreintes et de la propriété directe bénéficiaire qui en résulte. L’amendement indique un code d’acquisition A pour 31 206 actions restreintes acquises à un prix de 0 $ et les 31 206 actions ordinaires sous-jacentes. Après correction, Mme Pannu détient directement 36 275 actions ordinaires. Les actions restreintes sont soumises à vesting et vestiront à la première des dates: 28 juin 2025 ou la prochaine assemblée annuelle des actionnaires, sous réserve de certaines conditions de distribution. Le dépôt indique que l’amendement retire un Form 4 antérieur déposé par erreur et corrige les actions détenues indiquées précédemment.
Geraldine Pannu, Direktorin bei Processa Pharmaceuticals, Inc. (PCSA), hat ein geändertes Form 4 eingereicht, um die frühere Meldung ihrer eingeschränkten Aktien und der daraus resultierenden direkten wirtschaftlichen Eigentümerschaft zu korrigieren. Die Änderung offenbart einen Erwerbs-Code A für 31.206 Stücke eingeschränkter Aktien, die zu einem Preis von 0 $ erworben wurden, sowie darunter liegende 31.206 Stücke Stammaktien. Nach der Korrektur besitzt Frau Pannu direkt 36.275 Stammaktien. Die eingeschränkten Aktien unterliegen einer Vesting-Phase und werden am frühesten der 28. Juni 2025 oder der nächsten Jahreshauptversammlung der Aktionäre vesten, vorbehaltlich bestimmter Ausschüttungsanforderungen. Die Einreichung erklärt, dass das Amendment ein zuvor fehlerhaft eingereichtes Form 4 zurückzieht und die zuvor gemeldeten wirtschaftlich berechtigten Aktien korrigiert.
FAQ
What change did the Form 4/A for PCSA report about Geraldine Pannu's holdings?
Do the restricted shares held by the director have vesting conditions?
Did the Form 4/A indicate any sales or cash purchases by the reporting person?
Why was an amended Form 4 filed for PCSA?
How many shares does Geraldine Pannu beneficially own according to the amendment?
